** Shares in French biotechnology company Innate Pharma jump 8 pct as Citi initiates with a "buy"recommendation and 10 euros/share PT.
** French biotech this year: http://link.reuters.com/kag23w
** Innate tipped as a rarity in Europe -- a publicly listedimmuno-oncology company with 2 experimental drugs in late-stagetests and a licensing deal with Bristol-Myers Squibb.
** Innate takes a different approach from otherimmuno-oncology companies, which may make its products suitablefor inclusion in future cancer-fighting drug combinations.
** Several analysts forecasting sales of immune-boostingmedicines from companies like Bristol-Myers, Merck & Co,Roche and AstraZeneca could top $30 bln a year.
** Progress on range of new immuno-oncology treatments wasrecently highlighted at a major cancer congress in Madrid.
** Citi sees high probability of success for Innate's mostadvanced product, lirilumab, in an ongoing Phase II trial forleukemia, with earliest approval estimated in 2016. (RM: ben.hirschler.thomsonreuters.com@reuters.net)
Astrazeneca (AZN)
